A systematic review of the genetic mechanisms of dolutegravir resistance
Background Characterizing the mutations selected by the integrase strand transfer inhibitor
(INSTI) dolutegravir and their effects on susceptibility is essential for identifying viruses less …
(INSTI) dolutegravir and their effects on susceptibility is essential for identifying viruses less …
Persistent low-level viremia in persons living with HIV undertreatment: an unresolved status
C Crespo-Bermejo, ER de Arellano, V Lara-Aguilar… - Virulence, 2021 - Taylor & Francis
Antiretroviral therapy (ART) allows suppressed viremia to reach less than 50 copies/mL in
most treated persons living with HIV (PLWH). However, the existence of PLWH that show …
most treated persons living with HIV (PLWH). However, the existence of PLWH that show …
[HTML][HTML] Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV
NI Paton, J Musaazi, C Kityo, S Walimbwa… - … England Journal of …, 2021 - Mass Medical Soc
Abstract Background The World Health Organization recommends dolutegravir with two
nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human …
nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human …
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy …
M Aboud, R Kaplan, J Lombaard, F Zhang… - The Lancet infectious …, 2019 - thelancet.com
Background Doubts exist regarding optimal second-line treatment options for HIV-1-infected
patients in resource-limited settings. We assessed safety and efficacy of dolutegravir …
patients in resource-limited settings. We assessed safety and efficacy of dolutegravir …
[HTML][HTML] Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi: an observational cohort study
A Gupta-Wright, K Fielding, JJ van Oosterhout… - The Lancet …, 2020 - thelancet.com
Background Antiretroviral therapy (ART) scale-up in sub-Saharan Africa combined with
weak routine virological monitoring has driven increasing HIV drug resistance. We …
weak routine virological monitoring has driven increasing HIV drug resistance. We …
Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research
A new first-line antiretroviral therapy (ART) regimen containing dolutegravir is being rolled
out in low-income and middle-income countries (LMICs). In studies from predominantly high …
out in low-income and middle-income countries (LMICs). In studies from predominantly high …
[HTML][HTML] Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection …
NI Paton, J Musaazi, C Kityo, S Walimbwa, A Hoppe… - The Lancet …, 2022 - thelancet.com
Background WHO guidelines recommend dolutegravir plus two nucleoside reverse
transcriptase inhibitors (NRTIs) for second-line HIV therapy, with NRTI switching from first …
transcriptase inhibitors (NRTIs) for second-line HIV therapy, with NRTI switching from first …
Management of virologic failure and HIV drug resistance
SM McCluskey, MJ Siedner… - Infectious Disease Clinics, 2019 - id.theclinics.com
In 2014, the Joint United Nations Programme on HIV and AIDS established global targets
such that 90% of people with HIV will be diagnosed, 90% of those diagnosed will be on …
such that 90% of people with HIV will be diagnosed, 90% of those diagnosed will be on …
[HTML][HTML] Second-line HIV treatment failure in sub-Saharan Africa: A systematic review and meta-analysis
Background Increased second-line antiretroviral therapy (ART) failure rate narrows future
options for HIV/AIDS treatment. It has critical implications in resource-limited settings; …
options for HIV/AIDS treatment. It has critical implications in resource-limited settings; …
Effectiveness of protease inhibitor/nucleos (t) ide reverse transcriptase inhibitor–based second-line antiretroviral therapy for the treatment of human immunodeficiency …
Abstract Background In sub-Saharan Africa, 25.5 million people are living with human
immunodeficiency virus (HIV), representing 70% of the global total. The need for second-line …
immunodeficiency virus (HIV), representing 70% of the global total. The need for second-line …